ArticleMolecular biology reports2026
Multiplexed targeted mRNA profiling of alcohol-related liver disease reveals stage-specific dysregulation of signaling pathways.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlcohol-related liver disease (ALD) remains a leading indication for liver transplantation and a major cause of alcohol-attributable deaths worldwide. The molecular events driving extracellular matrix (ECM) accumulation are incompletely understood. In this study, we aimed to investigate stage-specific gene expression signatures in ALD. METHODS AND
resultsLiver biopsies from 50 adults with prior alcohol overuse were selected: No fibrosis (controls (F0), n = 10), mild/moderate fibrosis (F1-F2, n = 19), and advanced fibrosis/cirrhosis (F3-F4, n = 21). We performed multiplexed targeted profiling of 760 mRNAs, followed by analysis of differentially expressed genes (DEGs) and gene set enrichment analysis. Selected targets were validated on the protein level using immunohistochemistry. Mild/moderate fibrosis versus controls showed 80 DEGs (p < 0.01), 63 of which were downregulated. MLXIPL and FURIN, both involved in glucose and lipid metabolism, were downregulated. Pathways involved in ECM formation were enriched. Advanced fibrosis vs. controls showed 187 DEGs (p < 0.01), of which 94 were upregulated. These included fibrogenic and inflammatory mediators such as TGFB1, COL1A1/2, TIMP1, LGALS3, and S100A4. Genes involved in fatty acid, steroid, and lipid metabolism were significantly repressed. Advanced versus mild/moderate fibrosis showed 211 DEGs (p < 0.01), with an increase in TGF-β-driven ECM remodeling and inhibition of lipid and fatty-acid metabolism pathways. LGALS3 and S100A4 mRNA levels correlated with protein expression (R ≥ 0.41, p < 0.01).
conclusionALD is characterized by early downregulation of metabolic genes and upregulation of ECM formation, followed by coordinated induction of the TGF-β-centered fibrogenic pathway and further suppression of metabolic pathways. We identified stage-specific molecular alterations associated with ALD progression and LGALS3 and S100A4 as candidate biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.